Anti‑CEACAM5 antibody drug conjugates
Publication Number: US 20250321446 A1Filing Date: February 26, 2025 (earliest‑filed application)Publication Date: January 13, 2026 (publication of the granted patent) Assignee / Applicant: Bristol‑Myers Squibb Company What This Covers This patent relates to antibody‑drug conjugates (ADCs) targeting CEACAM5 (carcinoembryonic antigen‑related cell adhesion molecule 5) — a cell surface protein frequently overexpressed in several solid tumors, including colorectal, pancreatic, and lung cancers. The application claims: In essence, the invention combines BMS’s…
Pharmaceutical Formulations of Diazoxide Choline and Methods of Use
Assignee: Soleno Therapeutics, Inc. (and predecessors/licensors)Patent Number: US 10,058,557 B2Filed: (priority dates typically before 2017)Issued: September 4, 2018Expiration: ~2035 (subject to potential patent term extension) What This Patent Covers This patent covers novel pharmaceutical compositions and methods of use involving diazoxide choline controlled‑release formulations, including: The claims also cover methods of manufacturing and formulating the extended‑release tablets that…
Epigenetic Editing as a Cell Engineering Platform: Rewriting the Regulatory Genome
Epigenetic editing is emerging as a transformative platform in cell engineering, enabling precise modulation of gene expression without altering the underlying DNA sequence. By targeting DNA methylation, histone modifications, or chromatin architecture, scientists can tune cellular behavior, reprogram lineage potential, and correct disease-associated dysregulation. This approach represents a fundamental shift from conventional genome editing: rather…
BioTech IP Review 